1-3 of 3
Nuwan C. Kurukulasuriya
Close
Sort by
Journal Articles

Tafasitamab Plus Lenalidomide Versus Pola-BR, R2, and CAR T: Comparing Outcomes from RE-MIND2, an Observational, Retrospective Cohort Study in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Grzegorz S. Nowakowski, Dok Hyun Yoon, Patrizia Mondello, Erel Joffe, Isabelle Fleury, Anthea Peters, Richard Greil, Matthew Ku, Reinhard Marks, Kibum Kim, Pier Luigi Luigi Zinzani, Judith Trotman, Lorenzo Sabatelli, Dan Huang, Eva E. Waltl, Mark Winderlich, Sumeet Ambarkhane, Nuwan C. Kurukulasuriya, Raul Cordoba, Georg Hess, Gilles Salles
Journal: Blood
Blood (2021) 138 (Supplement 1): 183.
https://doi.org/10.1182/blood-2021-148302
Published: 2021
Journal Articles

Realmind: A Prospective, Multicenter, Observational Study of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Starting Second- or Third-Line Therapy and Not Receiving Autologous Stem Cell Transplant

Christopher R. Flowers, John M. Burke, Mirko Vukcevic, Susan Snodgrass, Shreekant Parasuraman, Thomas Büchele, Nuwan C. Kurukulasuriya
Journal: Blood
Blood (2021) 138 (Supplement 1): 5010.
https://doi.org/10.1182/blood-2021-148292
Published: 2021
Journal Articles

Preferences and Perceptions Regarding Treatment Decision-Making for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

Mallory Yung, Frederick Schnell, Mirko Vukcevic, Nuwan C. Kurukulasuriya
Journal: Blood
Blood (2021) 138 (Supplement 1): 1928.
https://doi.org/10.1182/blood-2021-146594
Published: 2021